Elevated Soluble Flt1 Inhibits Endothelial Repair in PR3-ANCA–Associated Vasculitis
Sandrine Roux(Inserm), Fádi Fakhouri(University Hospital of Lausanne), Régis Josien(Inserm), Étienne Larger(Inserm), Mélanie Néel(Inserm), Béatrice Charreau(Inserm), M. Hamidou(Centre Hospitalier Universitaire de Nantes), Emmanuelle Meffray(Inserm), Noël Lamandé(Inserm), Marie Rimbert(Inserm), H. Terence Cook(Imperial College Healthcare NHS Trust), Alexandre Dufay(Institut de Transplantation Urologie en Nephrologie), Alan D. Salama(The Royal Free Hospital), Ruth J. Pepper(University College Hospital), Maryvonne Hourmant
Cited by 43
Related Papers
C3 glomerulopathy: consensus report
|Kidney International|2013|635
Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids
|Annals of the Rheumatic Diseases|2013|454
Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials
|The Lancet|2020|445
Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids
|Nephrology Dialysis Transplantation|2009|156